Pharmathen announced today the acquisition of CBL Patras ("CBL"), a high-tech vertically integrated peptide production company approved by the US Food and Drug Administration (FDA).

Pharmathen has developed one of the most advanced portfolios of Long-Acting Injectable (LAI) products, Sustained Release Oral Solid formulations, and Ophthalmic products, produced at its facilities in Greece, which have received approval from both the FDA and the EU.

The acquisition of CBL confirms Pharmathen's commitment to innovation and dedication to long-term growth, further strengthening its position in the global therapeutic peptide market, valued at €38 billion today and expected to reach €100 billion by 2033.

CBL was founded in 1990 by Professor Kleomenis Barlos and is one of the key suppliers of peptide materials in Europe, offering peptide raw materials and intermediate peptides, as well as in-house and generally GMP-grade peptides on an industrial and commercial scale.

The Barlos family will continue to work closely with Pharmathen and the CBL management team, aiming to establish and provide the necessary support for the (vertically integrated) company's business activities on a global scale.

Mr. Dimitris Kadis, CEO of Pharmathen, stated: "We remain committed to our vision of improving the lives of our fellow human beings through innovation and access to affordable drugs and therapies. The acquisition is expected to create significant synergies both commercially and in terms of research, for both companies, accelerating our growth and further expanding the products and services we offer to our customers. By continuously investing in the development of our teams, we aim to create one of the most successful innovation hubs in our industry, strengthening our presence in a rapidly growing market. This acquisition marks a milestone for the company and reflects Partners Group's commitment to invest in and continuously drive sustainable growth for Pharmathen, starting from the acquisition of the company in January 2022."